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Although disturbances of the circadian system are strongly linked to affective disorders, no known studies have examined
melatonin proﬁles in young people in early stages of illness. In this study, 44 patients with an affective disorder underwent clinical
and neuropsychological assessments. They were then rated by a psychiatrist according to a clinical staging model and were
categorized as having an ‘attenuated syndrome’ or an ‘established disorder’. During the evening, salivary melatonin was sampled
under dim light conditions over an 8-h interval and for each patient, the time of melatonin onset, total area under the curve and
phase angle (difference between time of melatonin onset and time of habitual sleep onset) were computed. Results showed that
therewasnodifferenceinthetimingofmelatoninonsetacrossillnessstages.However,areaunderthecurveanalysesshowedthat
those patients with ‘established disorders’ had markedly reduced levels of melatonin secretion, and shorter phase angles, relative
to those with ‘attenuated syndromes’. These lower levels, in turn, were related to lower subjective sleepiness, and poorer
performance on neuropsychological tests of verbal memory. Overall, these results suggest that for patients with established
illness,dysfunctionofthecircadiansystemrelatesclearlytofunctionalfeaturesandmarkersofunderlyingneurobiologicalchange.
Althoughtheinterpretationoftheseresultswouldbegreatlyenhancedbycontroldata,thisworkhasimportantimplicationsforthe
early delivery of chronobiological interventions in young people with affective disorders.
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Introduction
Overthe last decade,there hasbeenincreasing interest inthe
relationship between the circadian system and affective
disorders. Various disruptions of circadian rhythms have
been described in depressive disorders, including shifts in the
onset and offset of the sleep phase relative to environmental
time (phase-advance or delay), as well as disruption to the
endogenous release of key hormones such as melatonin and
cortisol and changes in core body temperature rhythm.
1
Disruption to the rhythmicity of the systems under the control
of the circadian system is likely to represent a fundamental
disturbance of centrally regulated neurohormonal function,
and may well underpin many of the somatic symptoms so
often reported by patients with common mental disorders.
2
There is evidence to suggest that sleep and/or circadian
disturbance may be causally linked to both the emergence
and persistence of affective disorders (see review by Harvey
et al.
3 and Wulff et al.
4). Indeed, this notion is well supported
by studies conducted in patients with seasonal affective
disorder, where circadian misalignment has been linked with
the onset, extent and resolution of depressive symptoms.
5
Additionally, sleep–wake disturbance has been noted to be a
prodromal, inter-episodic and prognostic feature of bipolar
disorder (see review by Harvey et al.
3). Misalignment of the
circadian system relative to environmental time cues has
profound affects not only on mood, but also on cognition, and
a range of other physiological systems under circadian control,
including thermoregulatory, endocrinological, immunological,
cardiovascular and metabolic systems.
4,6,7 Together, these
data suggest that changes in the circadian system may not only
represent a potential biomarker for illness onset and progres-
sion but may also be associated with adverse health and
psychosocial outcomes.
The pattern of somatic features, sleep disturbance, daytime
fatigueand related anxietyand depressive symptomsthat often
emergesthroughouttheadolescentperiodindicatestheneedto
focus more closely on the underlying physiology of the
developing circadian system.
8 Developmental changes in the
sleep–wake and circadian systems are common inadolescents
and young adults, with delayed sleep phase syndrome a
commonfeatureofadolescence(seereviewbyCrowleyetal.
9).
Ithasbeenpostulatedthatchangestobothcircadiantimingand
period are explained largely by intrinsic biological drives, rather
than extrinsic environmental or psychosocial factors.
9
As altered sleep patterns may precede the onset and
persistenceof psychological distress in young people,
10 better
characterization of these features may lead to identiﬁcation of
vulnerability markers that can then underpin bettertargeting of
early interventions.
4,11 To date, there has been little attempt to
characterize these features in those at high risk or during the
onset phases of affective disorders.
4 Such objectives can,
however, be accomplished by utilizing novel clinical staging
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11,12 Within this framework, young
people presenting for care with admixtures of anxiety and
depressive symptoms are typicallycategorizedasbeingwithin
earlyor‘attenuatedsyndrome’phasesascomparedwiththose
with ‘established disorders’ (that is, ﬁrst episode of major
illness or later relapsing or persisting phases).
12,13 Concur-
rently with the longitudinal evaluation of this model, we are
testing whether there are distinct biomarkers evident at the
different phases of affective illness.
The aim of the present study was to examine circadian
parameters, notably the timing, secretion and synchrony of
melatonin, according to the clinical stage of affective illness.
12
Speciﬁcally, we aimed to examine melatonin onset and
secretion patterns in those with early ‘attenuated syndromes’
as compared with those with ‘established disorders’. It was
hypothesized that those in later stages of illness would exhibit
evidence of altered circadian functioning, in comparison with
those in early illness phases.
Subjects and methods
Participants. A total of 44 young individuals were recruited
from services that offer specialized assessment and early
intervention of mental health problems in young people
(Youth Mental Health Clinic (YMHC) at the Brain & Mind
Research Institute (BMRI); and headspace, Campbelltown,
Sydney, Australia
13,14). Inclusion criteria for this substudy
were: (1) individuals aged 12–30 years seeking professional
help primarily for signiﬁcant anxiety or depressive symptoms;
and (2) willingness to participate in overnight assessments of
circadian rhythms (salivary melatonin) and sleep.
Participants were excluded if they did not have sufﬁcient
English-language skills. The assessment protocol was
approved by the University of Sydney Human Research
Ethics Committee. Participants gave written informed
consent before participation in the study.
Clinical assessments. As described elsewhere,
12,13
patients entering the mental health services were assessed
and managed by medically and/or psychologically trained
health professionals. In this study, an independent psychiatrist
or trained research psychologist conducted a standardized
clinical interview, focussing on ratings of depressive symptom
severity (Hamilton Depression Rating Scale (HDRS))
15 as well
as assessment of the detailed criteria developed for formal
application of our clinical staging framework.
12 The clinical
stage of affective disorder was rated by two psychiatrists with
extensive clinical and research expertise in affective disorders
and staging paradigms (ES and IH). Patients were rated as
having either an ‘attenuated syndrome’ (stage 1b) or an
‘established disorder’ (stage 2 and above). Within this staging
system, patients may also be classiﬁed as being in ‘stage 1a’.
However, the stage 1a group is much more heterogeneous;
although they are help seeking, with mild symptoms, there is
subsequently less conﬁdence that such subjects would
transition to full-threshold disorders (see Hickie et al.
12).
Classiﬁcation at stage 2 or above depends on the
recognition of depressive syndromes with more severe
features (for example, agitation, psychomotor retardation,
psychotic features and additional intermittent hypomanic
features). Such disorders may traditionally be classiﬁed as
meeting full-threshold criteria for major depression according
to a DSM-IV (Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition) or ICD-10 (International Statistical
Classiﬁcation of Diseases and Related Health Problems, 10th
Revision) diagnosis, and later stages are characterized
predominantly by illness persistence or recurrence. Conse-
quently, 52 and 56% of participants in our study who were
classiﬁed as being in stage 1b and stage 2þ, respectively,
were taking antidepressant medications (w
2¼0.08, not
signiﬁcant (NS)). In comparison, 15% of those in stage 1b
were taking atypical antipsychotic medications as compared
with 63% of those in stage 2þ (w
2¼10.4, Po0.01).
Sleep and circadian assessment. As described
previously,
16 participants completed diaries and/or
actigraphy for 7 continuous days and nights before
circadian assessment. Habitual sleep onset (HSO) was
derived on a daily basis from a combination of light and
activity data, which was supplemented by diary information,
and averaged across the recording period. Participants then
attended the Chronobiology and Sleep Laboratory at the
BMRI for overnight circadian assessment. Participants were
asked to arrive 7h before their HSO, to familiarize with the
laboratory settings, and to ensure they were in a maintained
posture for at least 30min before the ﬁrst sample being
collected. As per standard dim light melatonin onset (DLMO)
protocols, saliva samples were collected at 30-min intervals
using Salivettes (Sarstedt, Germany) from 6h before HSO
until 2h after HSO. That is, participants were kept awake 2h
past their HSO. At all times, while in the laboratory,
participants were physiologically and behaviourally
monitored under controlled conditions, with ﬁxed light levels
(o50lx) and ambient temperature (24±11C). Participants
maintained a seated posture for at least 20min before each
sample collection.
Melatonin was assayed in 200ml saliva by double antibody
RIA (Cat no. RK-DSM2; Buhlmann Laboratories AG, Scho ¨-
nenbuch, Switzerland) according to the manufacturer’s
instructions. The lowest detectable level of melatonin was
4.3pM. The intra-assay coefﬁcient of variation was o10%
across the range of the standard curve. The inter-assay
coefﬁcient of variation was 15% at 19.5pM and 12.3% at
177pM. The total area under the curve (AUC) was calculated
using the trapezoid method, for each participant over the
entire 8-h sampling period. To determine the DLMO, the
average melatonin levels of the ﬁrst three sampling times was
calculated and a threshold of two standard deviations greater
than this value was established for each subject. The DLMO
was deﬁned as the time when the saliva melatonin level ﬁrst
exceededthisthresholdandremainedelevatedforatleastthe
next sampling time. The phase angle of entrainment was
calculated by subtracting the time of DLMO from HSO
(measured in min).
Self-report data. Patients were asked to complete the Beck
Depression Inventory-II for depressive symptom severity.
17
In order to assess daytime sleepiness in everyday or social
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Translational Psychiatrysituations, patients completed the Epworth Sleepiness
Scale.
18 Sleepiness during the evening of DLMO
assessment was rated using the Karolinska Sleepiness
Scale
19 (range¼1 ‘very alert’ to 9 ‘extremely sleepy-
ﬁghting sleep’). Ratings were obtained 3h before HSO
(KSS 3), and 1.5h after HSO (KSSþ1.5).
Neuropsychological assessment. Within 2 weeks of
laboratory assessment, a neuropsychologist administered the
Trailmaking Test Part A & Part B
20 to assess psychomotor
speed and set-shifting, respectively. Performance on this test
was converted to a z-score according to age matched
normative data.
21 The Rey Auditory Verbal Learning Test
(RAVLT)
22 was administered to measure unstructured verbal
learning. Total learning over the ﬁve trials was used (RAVLT-
encoding, maximum¼75) and scores were converted to z-
scores according to age- and education-adjusted normative
data.
23 We speciﬁcally chose to examine these two measures
as our prior work
24,25 has shown them to be sensitive to
underlying neurobiological changes in depressive disorders,
even in young people at early stages of illness.
26
Statistical analysis. Data were analysed using the Statistical
Package for Social Sciences (SPSS version 19, IBM, Chicago,
IL, USA). For continuous data, analyses employed Pearson’s
or Spearman’s correlations where appropriate. For analyses
between stage 1b and stage 2þ, all categorical data were
checked for distribution and normality. Student’s t-tests were
employed to analyse these data utilizing assumptions of equal
or unequal variance where appropriate. All analyses were two-
tailed and used an a level of 0.05.
Results
For three patients (n¼2, stage 1b and n¼1, stage 2þ),
melatonin data were not observed (within the sensitivity of the
assay) over the 8h sampling period. For another three
patients (n¼1, stage 1b and n¼2, stage 2þ), melatonin
was detected but did not reach the threshold as required by
the algorithm. Thus, DLMO and phase angle data were not
available on a total of six patients. Demographic, clinical and
DLMO data for the sample are presented in Table 1. There
was no difference in the time of DLMO between the clinical
stage groups. The stage 1b and stage 2þ groups did not
differ statistically in terms of their level of subjective sleepi-
ness 3h before HSO and 1.5h after HSO (KSS 3 and
KSSþ1.5), nor in their levels of daytime sleepiness, as
assessed by the Epworth Sleepiness Scale. As expected,
patients in earlier clinical stages were signiﬁcantly younger;
however,therewasnodifferenceingenderdistribution.There
was no signiﬁcant difference in HSO in the week before
assessment. However, stage 1b patients had signiﬁcantly
greater phase angles than stage 2þ patients when their
DLMO was compared with their HSO times.
Analysis of salivary melatonin AUC data for patients in stage
1b vs stage 2þ showed that those in earlier stages had almost
double the melatonin concentration of those in later stages
(Table 1 and Figure 1). This wasapparent for the entire sample
as well as for melatonin concentration 2h before and 2h after
HSO. Additionally, after controlling for age and depression
severity, these analyses remained signiﬁcant (total DLMO:
F3,36¼4.9, Po0.05; DLMO 2h before HSO: F3,36¼5.6,
Po0.05; and DLMO 2h after HBO: F3,36¼4.6, Po0.05).
Correlations with depressive symptoms. There was no
signiﬁcant association between salivary melatonin AUC and
either self-reported or clinician-rated depressive symptoms
for patients with stage 1b (Beck Depression Inventory (BDI),
r¼ 0.15, NS; HDRS, r¼ 0.15, NS) or stage 2þ (BDI,
r¼0.12, NS; HDRS, r¼0.37, NS) affective disorders.
Correlation with subjective sleepiness. For both staging
groups, there was no association between subjective
sleepiness 3h before HSO, and total salivary melatonin
AUC in the 3h before HSO (KSS 3: r¼ 0.17 and r¼0.28
for stage 1b and 2þ, respectively). However, lower levels of
salivary melatonin AUC 2h after HSO were related to
decreased levels of subjective sleepiness for those in stage
2þ only (KSSþ1.5: r¼0.5, Po0.05 and r¼0.29, NS for
stage 2þ and 1b, respectively).
Correlation with cognition. For those in stage 1b, there
were no signiﬁcant relationships between total salivary
melatonin AUC and performance on tasks of psychomotor
speed (Trailmaking Part A, r¼0.12, NS), new learning
(RAVLT-encoding, r¼ 0.04, NS) or set-shifting (Trailmaking
Part B, r¼ 0.06, NS). For those in stage 2þ, lower levels of
salivary melatonin AUC were not associated with processing
speed or set-shifting (Trailmaking Part A, r¼0.46, NS;
Trailmaking Part B, r¼0 . 3 2 ,N S ) .H o w e v e r ,a ss h o w ni n
Figure 2, lower melatonin levels were associated with poorer
performance on a task of verbal memory encoding (RAVLT-
encoding, r¼0.58, Po0.05).
Table 1 Demographic, psychiatric and circadian data for patients with stage 1b
(n¼28) and 2+ (n¼16) affective disorders
Stage 1b,
mean (s.d.)
Stage 2+,
mean (s.d.)
t-value
Age, years 20.5 (4.3) 23.2 (4.7)  2.2*
Sex, male/female
a 15/13 8/8 0.2
Hamilton Depression Rating scale 12.9 (6.5) 14.1 (8.3)  0.5
Education, years 12.6 (2.7) 12.6 (2.8)  0.4
Beck Depression Inventory
b 18.0 (8.6) 24.8 (11.1)  2.1*
Trailmaking Part A, z-score
b  0.0 (1.2) 0.2 (0.7)  0.7
Trailmaking Part B, z-score
b  0.3 (1.9)  0.4 (1.2) 0.3
RAVLT-encoding 0.27 (1.3)  0.48 (1.4) 1.7
Epworth Sleepiness scale 6.4 (3.7) 7.1 (4.1)  0.6
Habitual sleep onset, time 00:34 (01:27) 23:56 (01:12) 1.4
AUC, total sampled
b 142.3 (85.7) 69.3 (60.4) 2.7**
AUC, 2h before HSO
b 51.5 (38.8) 20.3 (22.0) 3.3**
AUC, 2h after HSO
b 85.2 (62.4) 42.1 (36.5) 2.8*
DLMO, time 21:43 (01:41) 22:23 (01:37)  1.2
Phase angle, min 169.08 (98.0) 90.0 (94.2) 2.4*
KSS 3 5.6 (2.1) 6.8 (1.6)  1.9
KSS+1.5 7.8 (1.9) 8.0 (1.4)  0.4
Abbreviations: AUC, area under the curve; DLMO, dim light melatonin onset;
KSS, Karolinska SleepinessScale; RAVLT, Rey AuditoryVerbalLearning Test.
*Po0.05, **Po0.01. All test statistics are Student’s t-test unless otherwise
speciﬁed;
aThe w
2 test;
bStudent’s t-test with unequal variances assumed. AUC
for melatonin over the sampling period (total sample), and for 2h before and
after habitual sleep onset; KSS 3h before habitual sleep onset (KSS 3), and
1.5hafterhabitual sleep onset(KSS+1.5). Notethat DLMOdata aremissing for
three patients in stage 1b and three patients in stage 2+ because of inability to
detect melatonin within the sensitivity of the assay or not reaching the threshold
as required by the algorithm.
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The present study has demonstrated that young people in
later stages (that is, ‘established disorders’) of major affective
disorders have signiﬁcantly lower salivary melatonin levels
assessed during the ﬁrst part of the melatonin secretory
period than those who are still at earlier stages of illness (that
is, ‘attenuated syndromes’). In turn, lower salivary melatonin
levels appeared to have functional correlates as they were
associated with decreased ratings of sleepiness. This ﬁnding
is consistent with previous studies describing the relationship
between melatonin and sleepiness levels.
27,28 The fact that
this was more apparent in the time after HSO is expected, as
this is when melatonin secretion would be elevated, although
it is important to note that there may be more variability in
melatoninlevelsduringthistime.Inaddition,thepresentstudy
has shown that differences in melatonin secretion proﬁles are
related to other markers of underlying neurobiology, namely
neuropsychological functioning. Speciﬁcally, lower melatonin
levels during the ﬁrst part of the night were related to poorer
performance on the encoding component of the RAVLT.
Performance on this task of unstructured verbal learning (that
is, word-list learning) is commonly compromised in patients
with affective disorders,
25,29 and in this sample, over two-
thirds of participants performed below average. As prior
work has demonstrated that poor performance may reﬂect
dysfunction in frontotemporal, including hippocampal circui-
try, these preliminary data may suggest that disturbances of
the circadian system and neuropsychological dysfunction
may reﬂect abnormalities in common underlying neural
circuitry. From these data, we cannot ascertain the temporal
relationship between dysfunction in the sleep and cognitive
systems, as neuropsychological testing did not occur at the
same time. Future studies may focus on delineating these
relationships further.
Regarding circadian timing, differences were not apparent
between the clinical staging groups, with DLMO occurring on
average at 2130 and 2200h for those with ‘attenuated
syndromes’ and ‘established disorders’, respectively. Inter-
estingly, for those in later clinical stages, the timing of
melatonin onset and habitual sleep onset occurred within
the expected 120-min period, whereas for those with
‘attenuated syndromes’, the difference in the timing of these
twosystemswasB3h.Althoughitisdifﬁculttointerpretthese
ﬁndings in the absence of a control group and full melatonin
proﬁle, these data may suggest that the circadian pacemaker
is phase-shifted (advanced) relative to timing of the sleep–
wake cycle. Alternatively, the sleep–wake timing may be
delayed, although it is noted that sleep onset is only weakly
inﬂuenced by the circadian system, and delays in sleep may
be due to a number of confounders. As we did not measure
peak melatonin amplitude in our current protocol, we cannot
ascertain whether there was attenuation in circadian ampli-
tude in this group. However, this seems unlikely as those with
‘attenuated syndromes’ did not have reduced melatonin
secretion (that is, the absolute amount of melatonin secretion
was higher) relative to those with ‘established disorders’.
Conversely, another possible explanation for these ﬁndings
could be that patients with ‘established disorders’ have a
shortened phase angle or even a phase delay, relative to
those at early stages of illness. As stated above, in the
absence of a control group and full melatonin proﬁle, further
studies are now required to delineate these possibilities. It is
also worth noting that a greater proportion of those with
‘establisheddisorders’weretakingantipsychoticmedications.
Although little is known about the effect of atypical
antipsychotics on circadian parameters, a preliminary study
has suggested that the older ‘typical’ antipsychotics have
disruptive effects on circadian rhythms.
30 Thus, we cannot
rule out the possible contribution of antipsychotic medication
to the disturbances in circadian parameters observed within
this study.
In terms of underlying circadian regulation of the sleep–
wake cycle, it is clear that the circadian clock in the anterior
hypothalamus is critical for establishing the circadian rhythm
of sleep–wake behaviour.
31 However, the suprachiasmatic
nucleus itself has only minimal monosynaptic outputs to
sleep–regulation centres such as the ventrolateral preoptic
nucleus and the lateral hypothalamus and has no outputs to
Figure 1 Graph demonstrating reduced salivary melatonin data (mean±s.e.m.)
for patients with stage 2þ affective disorders, relative to stage 1b. According to prior
actigraphy monitoring, habitual sleep onset would normally occur at sample 0.
Figure 2 Scatterplot demonstrating the relationship between decreased
salivary melatonin (area under curve) and memory performance (Rey Auditory
Verbal Learning Test (RAVLT)-encoding trials) for patients with stage 2þ (n¼15)
affective disorders. Note that neuropsychological assessment occurred within a 2-
week timeframe and did not occur in the evening of dim light melatonin onset
(DLMO) assessment.
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31 Thus, the weakened relationship
between the sleep and circadian systems in early-stage
patients (that is, as suggested by increased phase angles)
may reﬂect alterations in a multiple range of divergent
pathways. Indeed, recent models regarding synchrony of
thesleepandcircadiansystemshighlightthecriticalroleofthe
dorsomedial hypothalamic nucleus. The dorsomedial hy-
pothalamic nucleus sends a glutamatergic projection to the
lateral hypothalamus (overlapping with the ﬁeld of orexin-
containing neurons) as well as a GABAergic projection to the
ventrolateral preoptic nucleus.
31 Thus, desynchronization
between the sleep and circadian system may be because of
increased wake promotion via orexin neurons (resulting in a
delayed sleep phase despite homeostatic pressure) or a
reduction in amplitude of the circadian signal reaching the
ventrolateral preoptic nucleus.
32 As the dorsomedial hypotha-
lamicnucleusisverysensitivetoself-imposedschedules,and
integrates circadian signals with environmental and social
factors, behavioural feedback is recognized to be a critical
inﬂuence in sleep–wake patterns particularly to light exposure
and meal times. In this study, we cannot attribute the ﬁndings
regarding melatonin secretion and sleep timing in patients
with ‘attenuated syndromes’ to any particular process; there-
fore, further empirical studies speciﬁcally examining the
synchrony between these systems are now warranted.
Overall, these data suggest that with the emergence of
major mood disorders in young people, fundamental changes
in the sleep and circadian systems are occurring that are not
merely because of pubertal development, as commonly seen
in ‘healthy’ adolescents. Importantly, they highlight that
interventions targeting the circadian system are warranted
even in early phases of illness where there appears to be
some degree of misalignment of the sleep and circadian
systems. Asmore marked dysfunction in the circadian system
wasobserved in thosewith ‘established disorders’, these data
suggest that persistence of depressive symptoms may
perpetuate disruptions within the circadian system. Conver-
sely, persistent sleep–wake disturbance in young people may
contribute to ongoing psychological distress, an observation
that has been reported recently from epidemiological data.
10
In either case, these data indicate that differential interven-
tions may be required for those presenting at different clinical
stages. Speciﬁcally, behavioural interventions targeting de-
pressive symptoms and sleep–wake functioning concurrently
appear warranted in those with ‘attenuated syndromes’ and
sleep–wake disturbance. In ‘established disorders’, clinical
assessment should incorporate circadian markers (for exam-
ple, melatonin, core body temperature) where possible and
interventions may be much more targeted in order to address
the lowered levels of melatonin likely to be observed in this
group. Such agents may incorporate the use of pharmacolo-
gical compounds such as melatonin, melatonin analogues or
the newer antidepressants targeting both mood and sleep
symptoms (see Hickie and Rogers
1 for a review). Although at
this stage it is unclear whether circadian misalignment is
causally linked to cognitive dysfunction, or merely co-occurs
with neurobiological changes observed with the disease, it is
possible thatimprovements in both the moodand sleep–wake
systems will have broader beneﬁts for both cognition and
functional outcomes. In this regard, it is worth noting that the
decreased melatonin observed in this group was only weakly
associated with depressive symptom severity, suggesting
that interventions aiming to improve functioning should target
more than depressive symptoms alone.
Although the current study represents the ﬁrst to examine
circadian rhythms in young people with emerging affective
disorders, some limitations exist. First, as expected, those in
later stages had more severe disorders and, consequently,
greater numbers of patients had psychotic or hypomanic
features, and psychotropic use was more common in this
group. Second, although in the present study we measured
melatonin secretion under appropriate dim light conditions,
studies have shown that the timing of melatonin onset can be
inﬂuenced by light exposure the prior day.
33 Thus, some
variabilitybetweengroupsintermsoflightexposuremayhave
inﬂuenced these ﬁndings. Third, as this was not a longitudinal
study, we are uncertain whether patients move from a
weakened sleep–wake and circadian relationship early in
the course of disorder to a more compensated shift in sleep–
wake cycle (that is, with later sleep-onset (phase-delay) and
resynchronizing with the circadian rhythm).
In conclusion, this study presents the ﬁrst preliminary
ﬁndings suggesting that melatonin may be a viable marker of
affective disease progression and may assist with persona-
lized treatment planning. Future research may extend these
ﬁndings by examining the predictive utility of melatonin as a
biomarker for disease progression. It may also examine
whether individually tailored chronobiological interventions
provide more optimal treatment outcomes for young people
with affective disorders than conventional treatment ap-
proaches.
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